A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
Sponsor: Celgene
Terminated
Business objectives have changed.
This PHASE1 trial investigates Lymphoma and is currently terminated or withdrawn. Celgene leads this study, which shows 21 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Apr 2025 — May 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 16 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Brescia, Italy , Créteil, France , Lake Mary, United States , Leipzig, Germany , Lillie Cedex, France , Milan, Italy , Montpellier, France , Münster, Germany , Nantes, France and 12 more locations